US5880141A
(en)
|
1995-06-07 |
1999-03-09 |
Sugen, Inc. |
Benzylidene-Z-indoline compounds for the treatment of disease
|
DE69618587T2
(de)
*
|
1995-06-07 |
2002-08-29 |
Sugen Inc |
Chinazoline und pharmazeutische zusammensetzungen
|
US6906093B2
(en)
|
1995-06-07 |
2005-06-14 |
Sugen, Inc. |
Indolinone combinatorial libraries and related products and methods for the treatment of disease
|
US6316635B1
(en)
|
1995-06-07 |
2001-11-13 |
Sugen, Inc. |
2-indolinone derivatives as modulators of protein kinase activity
|
US6147106A
(en)
*
|
1997-08-20 |
2000-11-14 |
Sugen, Inc. |
Indolinone combinatorial libraries and related products and methods for the treatment of disease
|
US6696448B2
(en)
|
1996-06-05 |
2004-02-24 |
Sugen, Inc. |
3-(piperazinylbenzylidenyl)-2-indolinone compounds and derivatives as protein tyrosine kinase inhibitors
|
EP1014953B1
(de)
|
1997-03-05 |
2012-04-25 |
Sugen, Inc. |
Hydrophobe pharmazeutische wirkstoffe enthaltende zubereitungen
|
AR012634A1
(es)
|
1997-05-02 |
2000-11-08 |
Sugen Inc |
Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
|
US6316429B1
(en)
|
1997-05-07 |
2001-11-13 |
Sugen, Inc. |
Bicyclic protein kinase inhibitors
|
US6486185B1
(en)
|
1997-05-07 |
2002-11-26 |
Sugen, Inc. |
3-heteroarylidene-2-indolinone protein kinase inhibitors
|
US6316479B1
(en)
|
1997-05-19 |
2001-11-13 |
Sugen, Inc. |
Isoxazole-4-carboxamide compounds active against protein tryosine kinase related disorders
|
US6987113B2
(en)
|
1997-06-11 |
2006-01-17 |
Sugen, Inc. |
Tyrosine kinase inhibitors
|
US6130238A
(en)
*
|
1997-06-20 |
2000-10-10 |
Sugen, Inc. |
3-(cyclohexanoheteroarylidenyl)-2-indolinone protein tyrosine kinase inhibitors
|
US6051593A
(en)
*
|
1997-06-20 |
2000-04-18 |
Sugen, Inc. |
3-(cycloalkanoheteroarylidenyl)-2- indolinone protein tyrosine kinase inhibitors
|
US6114371A
(en)
*
|
1997-06-20 |
2000-09-05 |
Sugen, Inc. |
3-(cyclohexanoheteroarylidenyl)-2-indolinone protein tyrosine kinase inhibitors
|
US6313158B1
(en)
|
1997-06-20 |
2001-11-06 |
Sugen, Inc. |
Bioavailability of 3-heteroarylidenyl-2-indolinones active as protein tyrosine kinase inhibitors
|
US6235769B1
(en)
|
1997-07-03 |
2001-05-22 |
Sugen, Inc. |
Methods of preventing and treating neurological disorders with compounds that modulate the function of the C-RET receptor protein tyrosine kinase
|
US6133305A
(en)
|
1997-09-26 |
2000-10-17 |
Sugen, Inc. |
3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity
|
US6531502B1
(en)
|
1998-01-21 |
2003-03-11 |
Sugen, Inc. |
3-Methylidenyl-2-indolinone modulators of protein kinase
|
US6514981B1
(en)
|
1998-04-02 |
2003-02-04 |
Sugen, Inc. |
Methods of modulating tyrosine protein kinase function with indolinone compounds
|
US6569868B2
(en)
|
1998-04-16 |
2003-05-27 |
Sugen, Inc. |
2-indolinone derivatives as modulators of protein kinase activity
|
CA2314156C
(en)
|
1998-05-29 |
2010-05-25 |
Sugen, Inc. |
Pyrrole substituted 2-indolinone protein kinase inhibitors
|
CA2354591A1
(en)
|
1998-12-17 |
2000-06-22 |
F. Hoffmann-La Roche Ag |
4-aryloxindoles as inhibitors of jnk protein kinases
|
JP2002532492A
(ja)
*
|
1998-12-17 |
2002-10-02 |
エフ.ホフマン−ラ ロシュ アーゲー |
サイクリン−依存性キナーゼ、特にcdk2のインヒビターとしての4−アルケニル(及びアルキニル)オキシドール
|
US6153634A
(en)
|
1998-12-17 |
2000-11-28 |
Hoffmann-La Roche Inc. |
4,5-azolo-oxindoles
|
KR20010108024A
(ko)
|
1998-12-17 |
2001-12-07 |
프리돌린 클라우스너, 롤란드 비. 보레르 |
단백질 키나제 억제제로서의 4,5-피라진옥신돌
|
GB9904932D0
(en)
*
|
1999-03-04 |
1999-04-28 |
Glaxo Group Ltd |
Composition and method for preventing/reducing the severity of side effects of chemotherapy and/or radiation therapy
|
US7064114B2
(en)
|
1999-03-19 |
2006-06-20 |
Parker Hughes Institute |
Gel-microemulsion formulations
|
US6689806B1
(en)
|
1999-03-24 |
2004-02-10 |
Sugen, Inc. |
Indolinone compounds as kinase inhibitors
|
AU3770000A
(en)
*
|
1999-03-24 |
2000-10-09 |
Sugen, Inc. |
Indolinone compounds as kinase inhibitors
|
JP2000281588A
(ja)
*
|
1999-03-30 |
2000-10-10 |
Sankyo Co Ltd |
ガンの予防又は治療薬及びそのスクリーニング方法
|
AU4556800A
(en)
*
|
1999-04-27 |
2000-11-10 |
Smithkline Beecham Plc |
Novel treatment
|
US6380235B1
(en)
|
1999-05-04 |
2002-04-30 |
American Home Products Corporation |
Benzimidazolones and analogues
|
US6339098B1
(en)
|
1999-05-04 |
2002-01-15 |
American Home Products Corporation |
2,1-benzisothiazoline 2,2-dioxides
|
US6329416B1
(en)
|
1999-05-04 |
2001-12-11 |
American Home Products Corporation |
Combination regimens using 3,3-substituted indoline derivatives
|
US6358948B1
(en)
|
1999-05-04 |
2002-03-19 |
American Home Products Corporation |
Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
|
US6306851B1
(en)
|
1999-05-04 |
2001-10-23 |
American Home Products Corporation |
Cyclocarbamate and cyclic amide derivatives
|
US6358947B1
(en)
|
1999-05-04 |
2002-03-19 |
American Home Products Corporation |
Tetracyclic progesterone receptor modulator compounds and methods
|
US6355648B1
(en)
|
1999-05-04 |
2002-03-12 |
American Home Products Corporation |
Thio-oxindole derivatives
|
US6417214B1
(en)
|
1999-05-04 |
2002-07-09 |
Wyeth |
3,3-substituted indoline derivatives
|
US6391907B1
(en)
|
1999-05-04 |
2002-05-21 |
American Home Products Corporation |
Indoline derivatives
|
US6369056B1
(en)
|
1999-05-04 |
2002-04-09 |
American Home Products Corporation |
Cyclic urea and cyclic amide derivatives
|
US6407101B1
(en)
|
1999-05-04 |
2002-06-18 |
American Home Products Corporation |
Cyanopyrroles
|
US6498154B1
(en)
|
1999-05-04 |
2002-12-24 |
Wyeth |
Cyclic regimens using quinazolinone and benzoxazine derivatives
|
US6462032B1
(en)
|
1999-05-04 |
2002-10-08 |
Wyeth |
Cyclic regimens utilizing indoline derivatives
|
US6319912B1
(en)
|
1999-05-04 |
2001-11-20 |
American Home Products Corporation |
Cyclic regimens using 2,1-benzisothiazoline 2,2-dioxides
|
US6380178B1
(en)
|
1999-05-04 |
2002-04-30 |
American Home Products Corporation |
Cyclic regimens using cyclocarbamate and cyclic amide derivatives
|
US6509334B1
(en)
|
1999-05-04 |
2003-01-21 |
American Home Products Corporation |
Cyclocarbamate derivatives as progesterone receptor modulators
|
US6399593B1
(en)
|
1999-05-04 |
2002-06-04 |
Wyeth |
Cyclic regimens using cyclic urea and cyclic amide derivatives
|
US6423699B1
(en)
|
1999-05-04 |
2002-07-23 |
American Home Products Corporation |
Combination therapies using benzimidazolones
|
US6444668B1
(en)
|
1999-05-04 |
2002-09-03 |
Wyeth |
Combination regimens using progesterone receptor modulators
|
US6432979B1
(en)
|
1999-08-12 |
2002-08-13 |
American Cyanamid Company |
Method of treating or inhibiting colonic polyps and colorectal cancer
|
US6878733B1
(en)
|
1999-11-24 |
2005-04-12 |
Sugen, Inc. |
Formulations for pharmaceutical agents ionizable as free acids or free bases
|
US6313310B1
(en)
|
1999-12-15 |
2001-11-06 |
Hoffmann-La Roche Inc. |
4-and 5-alkynyloxindoles and 4-and 5-alkenyloxindoles
|
US20020010203A1
(en)
|
1999-12-22 |
2002-01-24 |
Ken Lipson |
Methods of modulating c-kit tyrosine protein kinase function with indolinone compounds
|
US6339100B1
(en)
*
|
1999-12-29 |
2002-01-15 |
The Trustees Of Columbia University In The City Of New York |
Methods for inhibiting mastocytosis
|
WO2001056557A2
(en)
*
|
2000-02-05 |
2001-08-09 |
Vertex Pharmaceuticals Incorporated |
Compositions useful as inhibitors of erk
|
US6620818B1
(en)
|
2000-03-01 |
2003-09-16 |
Smithkline Beecham Corporation |
Method for reducing the severity of side effects of chemotherapy and/or radiation therapy
|
UA73119C2
(en)
|
2000-04-19 |
2005-06-15 |
American Home Products Corpoir |
Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
|
MY128449A
(en)
|
2000-05-24 |
2007-02-28 |
Sugen Inc |
Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
|
CA2410509A1
(en)
|
2000-06-02 |
2001-12-13 |
Sugen, Inc. |
Indolinone derivatives as protein kinase/phosphatase inhibitors
|
GB0016454D0
(en)
|
2000-07-04 |
2000-08-23 |
Hoffmann La Roche |
Thienopyrrolidinones
|
CA2417500C
(en)
*
|
2000-07-28 |
2008-11-18 |
Georgetown University Medical Center |
Erbb-2 selective small molecule kinase inhibitors
|
DE60106947T2
(de)
*
|
2000-09-01 |
2005-11-10 |
Glaxo Group Ltd., Greenford |
Oxindolderivate
|
US6638965B2
(en)
|
2000-11-01 |
2003-10-28 |
Boehringer Ingelheim Pharma Kg |
Substituted indolinones, preparation thereof and their use as pharmaceutical compositions
|
DE10054019A1
(de)
*
|
2000-11-01 |
2002-05-23 |
Boehringer Ingelheim Pharma |
Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
|
EP1512413A3
(de)
|
2001-01-16 |
2009-09-23 |
Glaxo Group Limited |
Pharmazeutische Mischung gegen Krebs, die ein 4-Chinazolinamin in Kombination mit einem anderen antineoplastischen Wirkstoff enthält
|
JP2004529110A
(ja)
|
2001-03-06 |
2004-09-24 |
アストラゼネカ アクチボラグ |
脈管損傷活性を有するインドール誘導体
|
AU2002303892A1
(en)
|
2001-05-30 |
2002-12-09 |
Jingrong Cui |
5-aralkylsulfonyl-3- (pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
|
DE10134196B4
(de)
*
|
2001-07-13 |
2005-08-18 |
Forschungszentrum Karlsruhe Gmbh Technik Und Umwelt |
Pharmazeutische Zusammensetzung zur Hemmung der unkontrollierten Vermehrung und/oder Induzierung der Apoptose von Zellen
|
ATE343575T1
(de)
*
|
2001-09-27 |
2006-11-15 |
Smithkline Beecham Corp |
Azaoxoindol derivate als trk protein kinase hemmstoffe zur behandlung von krebs und chronischem schmerz
|
US20030187026A1
(en)
|
2001-12-13 |
2003-10-02 |
Qun Li |
Kinase inhibitors
|
US6797825B2
(en)
|
2001-12-13 |
2004-09-28 |
Abbott Laboratories |
Protein kinase inhibitors
|
US20030119839A1
(en)
*
|
2001-12-13 |
2003-06-26 |
Nan-Horng Lin |
Protein kinase inhibitors
|
GB0206861D0
(en)
*
|
2002-03-22 |
2002-05-01 |
Glaxo Group Ltd |
Medicaments
|
US6541504B1
(en)
*
|
2002-04-03 |
2003-04-01 |
Allergan Sales, Llc |
(3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors
|
CA2481036C
(en)
*
|
2002-04-03 |
2012-05-29 |
Allergan, Inc. |
(3z)-(3-(3-hydro-isobenzofuran-1-ylidene)-1,3-dihydro-2h-indol-2-ones as kinase inhibitors
|
AU2003221684A1
(en)
*
|
2002-04-08 |
2003-10-27 |
Smithkline Beecham Corporation |
Cancer treatment method comprising administering an erb-family inhibitor and a raf and/or ras inhibitor
|
US7514468B2
(en)
|
2002-07-23 |
2009-04-07 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions
|
ITMI20021620A1
(it)
*
|
2002-07-23 |
2004-01-23 |
Novuspharma Spa |
Composto ad ativita' antitumorale
|
US7169936B2
(en)
|
2002-07-23 |
2007-01-30 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Indolinone derivatives substituted in the 6-position, their preparation and their use as medicaments
|
DE60313339T2
(de)
*
|
2002-07-31 |
2008-01-03 |
Critical Outcome Technologies, Inc. |
Protein tyrosin kinase inhibitoren
|
US7825132B2
(en)
*
|
2002-08-23 |
2010-11-02 |
Novartis Vaccines And Diagnostics, Inc. |
Inhibition of FGFR3 and treatment of multiple myeloma
|
EP1539754A4
(de)
*
|
2002-08-23 |
2009-02-25 |
Novartis Vaccines & Diagnostic |
Benzimidazolchinolinone und deren verwendung
|
US8673924B2
(en)
|
2002-09-04 |
2014-03-18 |
Merck Sharp & Dohme Corp. |
Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
|
US8580782B2
(en)
|
2002-09-04 |
2013-11-12 |
Merck Sharp & Dohme Corp. |
Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
|
EP2194058B1
(de)
|
2002-09-04 |
2013-11-27 |
Merck Sharp & Dohme Corp. |
Zur Behandlung von Krebserkrankungen geeignete Pyrazolopyrimidine
|
AU2003273675A1
(en)
*
|
2002-10-09 |
2004-05-04 |
Wayne R. Danter |
Protein tyrosine kinase inhibitors
|
JP2006511616A
(ja)
*
|
2002-11-13 |
2006-04-06 |
カイロン コーポレイション |
癌の処置方法およびその関連方法
|
JP2006510727A
(ja)
*
|
2002-11-15 |
2006-03-30 |
エクセリクシス, インク. |
キナーゼモジュレーター
|
US20050019366A1
(en)
*
|
2002-12-31 |
2005-01-27 |
Zeldis Jerome B. |
Drug-coated stents and methods of use therefor
|
WO2004064733A2
(en)
*
|
2003-01-15 |
2004-08-05 |
Board Of Regents, University Of Texas System |
The use of c-raf inhibitors for the treatment of neurodegenerative diseases
|
BRPI0410704A
(pt)
*
|
2003-05-27 |
2006-06-13 |
Robert Per Hogerkvist |
uso de inibidor c-abl- tirosina quinase, pdgf-r- tirosina quinase, ou c-kit-tirosina quinase no tratamento da diabete
|
AR045037A1
(es)
|
2003-07-10 |
2005-10-12 |
Aventis Pharma Sa |
Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion.
|
AU2004281151A1
(en)
*
|
2003-10-16 |
2005-04-28 |
Novartis Vaccines And Diagnostics, Inc. |
Substituted benzazoles and use thereof as inhibitors of Raf kinase
|
EA012621B1
(ru)
*
|
2003-11-07 |
2009-10-30 |
Чирон Корпорейшн |
Фармацевтически приемлемые соли хинолиноновых соединений с улучшенными фармацевтическими свойствами
|
WO2005068424A1
(en)
*
|
2004-01-20 |
2005-07-28 |
Cell Therapeutics Europe S.R.L. |
Indolinone derivatives as receptor tyrosine kinase ihibitors
|
JPWO2005080392A1
(ja)
|
2004-02-19 |
2007-08-02 |
武田薬品工業株式会社 |
ピラゾロキノロン誘導体およびその用途
|
AU2005216904B2
(en)
*
|
2004-02-20 |
2010-11-25 |
Novartis Vaccines And Diagnostics, Inc. |
Modulation of inflammatory and metastatic processes
|
DE102004012070A1
(de)
*
|
2004-03-12 |
2005-09-29 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue cycloalkyl-haltige 5-Acylindolinone, deren Herstellung und deren Verwendung als Arzneimittel
|
US7759383B2
(en)
|
2005-02-22 |
2010-07-20 |
The Regents Of The University Of Michigan |
Small molecule inhibitors of MDM2 and the uses thereof
|
KR101319122B1
(ko)
*
|
2005-05-13 |
2013-10-23 |
노파르티스 아게 |
약물 저항성 암을 치료하는 방법
|
EP2270000B1
(de)
*
|
2005-05-23 |
2015-07-29 |
Novartis AG |
Kristalline und andere Formen von 4-Amino-5-Fluor-3-[6-(Methylpiperazin-1-yl)-1H-Benzimidazol-2-yl]-1H-Chinolin-2-on-Milchsäuresalz
|
PE20070427A1
(es)
*
|
2005-08-30 |
2007-04-21 |
Novartis Ag |
Compuestos derivados de benzimidazoles sustituidos como inhibidores de tirosina quinasas
|
CA2627544C
(en)
*
|
2005-11-29 |
2015-07-07 |
Novartis Ag |
Formulations of quinolinones for the treatment of cancer
|
US8546404B2
(en)
|
2005-12-13 |
2013-10-01 |
Merck Sharp & Dohme |
Compounds that are ERK inhibitors
|
KR20080103996A
(ko)
|
2006-02-16 |
2008-11-28 |
쉐링 코포레이션 |
Erk 억제제로서 피롤리딘 유도체
|
BRPI0715423A2
(pt)
*
|
2006-07-21 |
2013-07-02 |
Novartis Ag |
formulaÇÕes para Éteres de benzimidazolil piridila
|
AU2007340265B2
(en)
*
|
2006-09-19 |
2012-07-26 |
Novartis Ag |
Biomarkers of target modulation, efficacy, diagnosis and/or prognosis for Raf inhibitors
|
JP5571387B2
(ja)
|
2007-01-11 |
2014-08-13 |
クリティカル・アウトカム・テクノロジーズ・インコーポレイテッド |
癌の治療のための化合物および方法
|
US8138191B2
(en)
|
2007-01-11 |
2012-03-20 |
Critical Outcome Technologies Inc. |
Inhibitor compounds and cancer treatment methods
|
KR100799821B1
(ko)
*
|
2007-02-05 |
2008-01-31 |
동화약품공업주식회사 |
신규한 이마티닙 캠실레이트 및 그의 제조방법
|
UY30892A1
(es)
|
2007-02-07 |
2008-09-02 |
Smithkline Beckman Corp |
Inhibidores de la actividad akt
|
UY30915A1
(es)
|
2007-02-16 |
2008-09-02 |
Smithkline Beecham Corp |
Método de tratamiento de canceres
|
US20110129550A1
(en)
*
|
2007-02-16 |
2011-06-02 |
Connie Erickson-Miller |
Cancer treatment method
|
US20110160130A1
(en)
*
|
2007-02-16 |
2011-06-30 |
Connie Erickson-Miller |
Cancer treatment method
|
WO2008134124A1
(en)
*
|
2007-04-30 |
2008-11-06 |
The Uab Research Foundation |
Ul97 inhibitors for treatment of proliferative disorders
|
PE20090717A1
(es)
|
2007-05-18 |
2009-07-18 |
Smithkline Beecham Corp |
Derivados de quinolina como inhibidores de la pi3 quinasa
|
EP2162445B1
(de)
|
2007-06-05 |
2013-11-27 |
Takeda Pharmaceutical Company Limited |
Heterobicyclische verbindungen als kinasehemmer
|
US8324395B2
(en)
|
2007-08-23 |
2012-12-04 |
Takeda Pharmaceutical Company Limited |
Heterocyclic compound and use thereof
|
WO2009028629A1
(ja)
|
2007-08-29 |
2009-03-05 |
Takeda Pharmaceutical Company Limited |
複素環化合物およびその用途
|
DK2197878T3
(en)
*
|
2007-09-06 |
2016-11-14 |
Boston Biomedical Inc |
FORMATIONS OF kinase inhibitors AND USE THEREOF FOR THE TREATMENT OF CANCER AND OTHER DISEASES RELATED TO kinases
|
CA2709224C
(en)
*
|
2007-10-09 |
2015-06-23 |
The Trustees Of The University Of Pennsylvania |
Thrombopoietin receptor agonist (tpora) kills acute human myeloid leukemia cells
|
CA2709536C
(en)
|
2007-12-21 |
2016-05-31 |
University Health Network |
Indazolyl, benzimidazolyl, benzotriazolyl substituted indolinone derivatives as kinase inhibitors useful in the treatment of cancer
|
US8466151B2
(en)
*
|
2007-12-26 |
2013-06-18 |
Critical Outcome Technologies, Inc. |
Compounds and method for treatment of cancer
|
MY152271A
(en)
|
2008-02-21 |
2014-09-15 |
Merck Sharp & Dohme |
Novel compounds that are erk inhibitors
|
WO2010059658A1
(en)
|
2008-11-20 |
2010-05-27 |
Glaxosmithkline Llc |
Chemical compounds
|
JP5579619B2
(ja)
|
2008-12-01 |
2014-08-27 |
武田薬品工業株式会社 |
複素環化合物およびその用途
|
JO3101B1
(ar)
|
2008-12-02 |
2017-09-20 |
Takeda Pharmaceuticals Co |
مشتقات بنزوثيازول كعوامل مضادة للسرطان
|
UY32306A
(es)
|
2008-12-09 |
2010-07-30 |
Gilead Sciences Inc |
Derivados de pteridinona y pirimidinodiazepinona y composiciones farmacéuticas que modulan en forma selectiva los receptores tipo toll, métodos y usos
|
US20110288142A1
(en)
|
2009-01-30 |
2011-11-24 |
Chen Pingyun Y |
CRYSTALLINE N--5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride
|
WO2010100127A1
(en)
|
2009-03-04 |
2010-09-10 |
Novartis Ag |
Disubstituted imidazole derivatives as modulators of raf kinase
|
EP2417127B1
(de)
|
2009-04-06 |
2014-02-26 |
University Health Network |
Kinasehemmer und verfahren zur krebsbehandlung damit
|
JP5554833B2
(ja)
|
2009-05-20 |
2014-07-23 |
グラクソスミスクライン エルエルシー |
Pi3キナーゼ阻害剤としてのチアゾロピリミジノン誘導体
|
MY162604A
(en)
|
2009-08-17 |
2017-06-30 |
Intellikine Llc |
Heterocyclic compounds and uses thereof
|
KR101781658B1
(ko)
|
2009-08-21 |
2017-10-23 |
노파르티스 아게 |
암의 치료 방법
|
CA2771890A1
(en)
|
2009-08-26 |
2011-03-03 |
Fabrice Pierre |
Condensed quinolines as protein kinase modulators
|
AR077975A1
(es)
|
2009-08-28 |
2011-10-05 |
Irm Llc |
Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
|
US8242260B2
(en)
|
2009-08-28 |
2012-08-14 |
Novartis Ag |
Compounds and compositions as protein kinase inhibitors
|
PL2477987T3
(pl)
|
2009-09-14 |
2018-06-29 |
Gilead Sciences, Inc. |
Modulatory receptorów toll-podobnych
|
SI2488033T1
(sl)
|
2009-10-16 |
2019-10-30 |
Novartis Ag |
Kombinacija, ki vsebuje inhibitor MEK in inhibitor B-RAF
|
US8507507B2
(en)
|
2009-10-22 |
2013-08-13 |
Gilead Sciences, Inc. |
Modulators of toll-like receptors
|
US20150018301A1
(en)
*
|
2009-11-06 |
2015-01-15 |
The Johns Hopkins University |
LRRK-2-Mediated Neuronal Toxicity
|
JP5728499B2
(ja)
|
2010-02-05 |
2015-06-03 |
アイアールエム・リミテッド・ライアビリティ・カンパニーIrm,Llc |
タンパク質キナーゼ阻害剤としての化合物および組成物
|
US8598156B2
(en)
|
2010-03-25 |
2013-12-03 |
Glaxosmithkline Llc |
Chemical compounds
|
CA2999435A1
(en)
|
2010-04-01 |
2011-10-06 |
Critical Outcome Technologies Inc. |
Compounds and method for treatment of hiv
|
WO2011123947A1
(en)
|
2010-04-06 |
2011-10-13 |
University Health Network |
Synthesis of chiral 2-(1h-indazol-6-yl)-spiro[cyclopropane-1,3'- indolin]-2'-ones
|
EP2585454A1
(de)
|
2010-06-25 |
2013-05-01 |
Novartis AG |
Heteroarylverbindungen und zusammensetzungen als proteinkinasehemmer
|
JP6185839B2
(ja)
|
2010-09-14 |
2017-08-23 |
ノバルティス アーゲー |
Braf阻害薬とvegf阻害薬との組み合わせ
|
CA2812608C
(en)
|
2010-10-06 |
2020-07-14 |
Glaxosmithkline Llc |
Benzimidazole derivatives as pi3 kinase inhibitors
|
GB201112607D0
(en)
|
2011-07-22 |
2011-09-07 |
Glaxo Group Ltd |
Novel compounds
|
TWI505828B
(zh)
|
2010-12-20 |
2015-11-01 |
葛蘭素史克智慧財產(第二)有限公司 |
新穎醫藥組成物
|
CN103298345B
(zh)
|
2011-01-11 |
2016-12-14 |
诺瓦蒂斯公司 |
组合
|
US9127000B2
(en)
|
2011-02-23 |
2015-09-08 |
Intellikine, LLC. |
Heterocyclic compounds and uses thereof
|
EP2776037B1
(de)
|
2011-11-11 |
2019-01-09 |
Novartis AG |
Methode zur behandlung einer proliferativen erkrankung
|
KR102091295B1
(ko)
|
2011-11-23 |
2020-03-19 |
어레이 바이오파마 인크. |
제약 제제
|
KR20140117644A
(ko)
|
2012-01-31 |
2014-10-07 |
스미스클라인 비이참 (코르크) 리미티드 |
암을 치료하는 방법
|
WO2013143597A1
(en)
|
2012-03-29 |
2013-10-03 |
Glaxo Group Limited |
Demethylase enzymes inhibitors
|
JP6430390B2
(ja)
|
2012-11-20 |
2018-11-28 |
ジェネンテック, インコーポレイテッド |
T790mを含むegfr変異体の阻害剤としてのアミノピリミジン化合物
|
EA028246B1
(ru)
|
2012-11-30 |
2017-10-31 |
ГЛЭКСОСМИТКЛАЙН ЭлЭлСи |
Фармацевтическая композиция
|
JP2016504409A
(ja)
|
2013-01-09 |
2016-02-12 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー2、リミテッドGlaxosmithkline Intellectual Property No.2 Limited |
組合せ
|
WO2014108858A1
(en)
|
2013-01-10 |
2014-07-17 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Fatty acid synthase inhibitors
|
GB201311910D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel Compounds
|
EP2970206A1
(de)
*
|
2013-03-13 |
2016-01-20 |
Boston Biomedical, Inc. |
3-(aryl- oder heteroaryl)-methylenindolin-2-on-derivate als hemmer von krebsstammzellenbahnpfadkinasen zur krebsbehandlung
|
US9242969B2
(en)
|
2013-03-14 |
2016-01-26 |
Novartis Ag |
Biaryl amide compounds as kinase inhibitors
|
WO2014151147A1
(en)
|
2013-03-15 |
2014-09-25 |
Intellikine, Llc |
Combination of kinase inhibitors and uses thereof
|
KR20160013049A
(ko)
|
2013-06-03 |
2016-02-03 |
노파르티스 아게 |
항-pd-l1 항체 및 mek 억제제 및/또는 braf 억제제의 조합물
|
EP3052494B1
(de)
|
2013-06-28 |
2018-12-26 |
H. Hoffnabb-La Roche Ag |
Azaindazolverbindungen als inhibitoren von t790m-haltigen egfr-mutanten
|
GB201311888D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
GB201311891D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compound
|
RU2016116915A
(ru)
|
2013-10-01 |
2017-11-13 |
Новартис Аг |
Комбинация
|
BR112016006970A2
(pt)
|
2013-10-01 |
2017-08-01 |
Novartis Ag |
enzalutamida em combinação com afuresertib para o tratamento de câncer
|
WO2015056180A1
(en)
|
2013-10-15 |
2015-04-23 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Indoline derivatives as inhibitors of perk
|
KR102195494B1
(ko)
|
2013-10-18 |
2020-12-28 |
유니버시티 헬스 네트워크 |
췌장암 치료
|
KR20160088884A
(ko)
|
2013-12-12 |
2016-07-26 |
노파르티스 아게 |
암의 치료를 위한 트라메티닙, 파니투무맙 및 다브라페닙의 조합물
|
EP3111222A1
(de)
|
2014-02-26 |
2017-01-04 |
Glaxosmithkline Intellectual Property (No. 2) Limited |
Verfahren zur behandlung von krebspatienten mit reaktion auf ezh2-inhibitor gsk126
|
CN106456642A
(zh)
|
2014-03-12 |
2017-02-22 |
诺华股份有限公司 |
含btk抑制剂与akt抑制剂的组合
|
WO2016001907A1
(en)
|
2014-07-02 |
2016-01-07 |
Prendergast Patrick T |
Mogroside iv and mogroside v as agonist/stimulator/un-blocking agent for toll-like receptor 4 and adjuvant for use in human/animal vaccine and to stimulate immunity against disease agents.
|
TWI806081B
(zh)
|
2014-07-11 |
2023-06-21 |
美商基利科學股份有限公司 |
用於治療HIV之toll樣受體調節劑
|
UY36294A
(es)
|
2014-09-12 |
2016-04-29 |
Novartis Ag |
Compuestos y composiciones como inhibidores de quinasa
|
PT3194401T
(pt)
|
2014-09-16 |
2020-12-23 |
Gilead Sciences Inc |
Formas sólidas de modulador de recetor tipo toll
|
WO2016055935A1
(en)
|
2014-10-06 |
2016-04-14 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Combination of lysine-specific demethylase 1 inhibitor and thrombopoietin agonist
|
WO2016059602A2
(en)
|
2014-10-16 |
2016-04-21 |
Glaxo Group Limited |
Methods of treating cancer and related compositions
|
MA41414A
(fr)
|
2015-01-28 |
2017-12-05 |
Centre Nat Rech Scient |
Protéines de liaison agonistes d' icos
|
GB201506871D0
(en)
|
2015-04-22 |
2015-06-03 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
EP3331918A1
(de)
|
2015-08-04 |
2018-06-13 |
GlaxoSmithKline Intellectual Property Development Limited |
Kombinationsbehandlungen und verwendungen und verfahren dafür
|
BR112018002436A2
(pt)
|
2015-08-04 |
2018-09-18 |
Glaxosmithkline Ip Dev Ltd |
tratamento de combinação de usos de métodos destes
|
US20180222990A1
(en)
|
2015-08-04 |
2018-08-09 |
Glaxosmithkline Intellectual Property Development Limited |
Combination Treatments and Uses and Methods Thereof
|
WO2017021912A1
(en)
|
2015-08-06 |
2017-02-09 |
Glaxosmithkline Intellectual Property Development Limited |
Combined tlrs modulators with anti ox40 antibodies
|
WO2017021792A1
(en)
|
2015-08-06 |
2017-02-09 |
Glaxosmithkline Biologicals Sa |
Tlr4 agonists and compositions thereof and their use in the treatment of cancer
|
TW201716084A
(zh)
|
2015-08-06 |
2017-05-16 |
葛蘭素史克智慧財產發展有限公司 |
組合物及其用途與治療
|
WO2017025871A1
(en)
|
2015-08-07 |
2017-02-16 |
Glaxosmithkline Intellectual Property Development Limited |
Combination therapy comprising anti ctla-4 antibodies
|
CA3006934A1
(en)
|
2015-12-01 |
2017-06-08 |
Glaxosmithkline Intellectual Property Development Limited |
Combination of antibodies targeting bcma, pd-1 and ox40 in cancer treatments and uses therof
|
NZ738202A
(en)
|
2015-12-03 |
2019-07-26 |
Glaxosmithkline Ip Dev Ltd |
Cyclic purine dinucleotides as modulators of sting
|
WO2017098421A1
(en)
|
2015-12-08 |
2017-06-15 |
Glaxosmithkline Intellectual Property Development Limited |
Benzothiadiazine compounds
|
WO2017153952A1
(en)
|
2016-03-10 |
2017-09-14 |
Glaxosmithkline Intellectual Property Development Limited |
5-sulfamoyl-2-hydroxybenzamide derivatives
|
CN114230625A
(zh)
|
2016-03-18 |
2022-03-25 |
免疫传感器公司 |
环二核苷酸化合物及使用方法
|
JP6746712B2
(ja)
|
2016-04-07 |
2020-08-26 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited |
タンパク質調節因子として有用な複素環式アミド
|
SG11201808708RA
(en)
|
2016-04-07 |
2018-11-29 |
Glaxosmithkline Ip Dev Ltd |
Heterocyclic amides useful as protein modulators
|
WO2018015879A1
(en)
|
2016-07-20 |
2018-01-25 |
Glaxosmithkline Intellectual Property Development Limited |
Isoquinoline derivatives as perk inhibitors
|
EP3494140A1
(de)
|
2016-08-04 |
2019-06-12 |
GlaxoSmithKline Intellectual Property Development Ltd |
Anti-icos- und anti-pd-1-antikörper-kombinationstherapie
|
US20180072711A1
(en)
|
2016-09-15 |
2018-03-15 |
Arvinas, Inc. |
Indole derivatives as estrogen receptor degraders
|
AU2017329090B9
(en)
|
2016-09-19 |
2019-09-05 |
Novartis Ag |
Therapeutic combinations comprising a RAF inhibitor and a ERK inhibitor
|
BR112019012878A2
(pt)
|
2016-12-23 |
2019-11-26 |
Arvinas Operations Inc |
compostos e métodos para a degradação alvo de polipeptídos de fibrossarcoma rapidamente acelerados
|
US10994015B2
(en)
|
2016-12-23 |
2021-05-04 |
Arvinas Operations, Inc. |
EGFR proteolysis targeting chimeric molecules and associated methods of use
|
US20190375847A1
(en)
|
2017-02-15 |
2019-12-12 |
Glaxosmithkline Intellectual Property Development Limited |
Combination treatment for cancer
|
JP2019529343A
(ja)
|
2017-07-05 |
2019-10-17 |
ノバルティス アーゲー |
新規な医薬組成物
|
WO2019021208A1
(en)
|
2017-07-27 |
2019-01-31 |
Glaxosmithkline Intellectual Property Development Limited |
USEFUL INDAZOLE DERIVATIVES AS PERK INHIBITORS
|
UY37866A
(es)
|
2017-09-07 |
2019-03-29 |
Glaxosmithkline Ip Dev Ltd |
Nuevos compuestos derivados de benzoimidazol sustituidos que reducen la proteína myc (c-myc) en las células e inhiben la histona acetiltransferasa de p300/cbp.
|
WO2019053617A1
(en)
|
2017-09-12 |
2019-03-21 |
Glaxosmithkline Intellectual Property Development Limited |
CHEMICAL COMPOUNDS
|
EP3692033A1
(de)
|
2017-10-05 |
2020-08-12 |
GlaxoSmithKline Intellectual Property Development Limited |
Modulatoren des stimulators von interferongenen (sting) zur verwendung bei der behandlung von hiv
|
CN111417630B
(zh)
|
2017-10-05 |
2023-06-06 |
葛兰素史克知识产权开发有限公司 |
干扰素基因刺激因子(sting)的调节剂
|
WO2019106605A1
(en)
|
2017-12-01 |
2019-06-06 |
Board Of Regents, The University Of Texas System |
Combination treatment for cancer
|
GB201807924D0
(en)
|
2018-05-16 |
2018-06-27 |
Ctxt Pty Ltd |
Compounds
|
WO2020030571A1
(en)
|
2018-08-06 |
2020-02-13 |
Glaxosmithkline Intellectual Property Development Limited |
Combinations of a pd-1 antibody and a tlr4 modulator and uses thereof
|
WO2020030570A1
(en)
|
2018-08-06 |
2020-02-13 |
Glaxosmithkline Intellectual Property Development Limited |
Combinations of an ox40 antibody and a tlr4 modulator and uses thereof
|
CN112771023B
(zh)
*
|
2018-08-07 |
2024-04-09 |
信力生技股份有限公司 |
3–(3,5–二溴–4–羟基亚苄基)–5–吲哚基–1,3–二氢吲哚基–2–酮的铵盐及其用途
|
CA3113014A1
(en)
*
|
2018-09-18 |
2020-03-26 |
1Globe Biomedical Co., Ltd. |
Treatment for obesity
|
EP4342473A3
(de)
|
2018-11-30 |
2024-05-15 |
GlaxoSmithKline Intellectual Property Development Limited |
Verbindungen zur verwendung in der hiv-therapie
|
WO2020160365A1
(en)
|
2019-02-01 |
2020-08-06 |
Glaxosmithkline Intellectual Property Development Limited |
Belantamab mafodotin in combination with pembrolizumab for treating cancer
|
JP2022533194A
(ja)
|
2019-05-16 |
2022-07-21 |
スティングセラ インコーポレイテッド |
ベンゾ[b][1,8]ナフチリジン酢酸誘導体および使用方法
|
WO2020232375A1
(en)
|
2019-05-16 |
2020-11-19 |
Silicon Swat, Inc. |
Oxoacridinyl acetic acid derivatives and methods of use
|
AU2020308053A1
(en)
|
2019-06-26 |
2022-01-20 |
Glaxosmithkline Intellectual Property Development Limited |
IL1RAP binding proteins
|
GB201910305D0
(en)
|
2019-07-18 |
2019-09-04 |
Ctxt Pty Ltd |
Compounds
|
GB201910304D0
(en)
|
2019-07-18 |
2019-09-04 |
Ctxt Pty Ltd |
Compounds
|
WO2021043961A1
(en)
|
2019-09-06 |
2021-03-11 |
Glaxosmithkline Intellectual Property Development Limited |
Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and chemotherapy
|
WO2021046289A1
(en)
|
2019-09-06 |
2021-03-11 |
Glaxosmithkline Intellectual Property Development Limited |
Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and ipilimumab
|
JP2023512023A
(ja)
|
2020-01-28 |
2023-03-23 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド |
併用療法及びその使用及び方法
|
CN114573453A
(zh)
*
|
2020-12-02 |
2022-06-03 |
荆楚理工学院 |
一种选择性的羧酸酯裂解方法
|
JPWO2023008462A1
(de)
|
2021-07-27 |
2023-02-02 |
|
|
KR102566028B1
(ko)
*
|
2021-08-10 |
2023-08-10 |
계명대학교 산학협력단 |
신규한 다중 단백질 키나아제 억제제
|
WO2023230541A1
(en)
|
2022-05-27 |
2023-11-30 |
Viiv Healthcare Company |
Piperazine derivatives useful in hiv therapy
|
US11957759B1
(en)
|
2022-09-07 |
2024-04-16 |
Arvinas Operations, Inc. |
Rapidly accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use
|